|
Group
|
N
|
Type
|
Positive participants
|
Positive rate (%)
|
GMT
|
Participants with different titers (1:)
|
|---|
|
< 8
|
8 ~ < 32
|
≥32
|
|---|
|
1
|
109
|
I
|
82
|
75.23
|
17.57
|
27
|
47
|
35
|
|
II
|
49
|
44.95
|
8.39
|
60
|
33
|
16
|
|
III
|
29
|
26.61
|
6.13
|
80
|
20
|
9
|
|
2
|
125
|
I
|
98
|
78.40
|
18.44
|
27
|
50
|
48
|
|
II
|
43
|
34.40
|
6.73
|
82
|
30
|
13
|
|
III
|
23
|
18.40
|
5.33
|
102
|
19
|
4
|
|
3
|
127
|
I
|
90
|
70.87
|
17.99
|
37
|
39
|
51
|
|
II
|
46
|
36.22
|
6.69
|
81
|
35
|
11
|
|
III
|
21
|
16.54
|
5.59
|
106
|
14
|
7
|
|
4
|
124
|
I
|
96
|
77.42
|
21.21
|
28
|
40
|
56
|
|
II
|
47
|
37.90
|
6.44
|
77
|
42
|
5
|
|
III
|
33
|
26.61
|
6.41
|
91
|
23
|
10
|
|
5
|
124
|
I
|
95
|
76.61
|
19.15
|
29
|
45
|
50
|
|
II
|
46
|
37.10
|
6.92
|
78
|
36
|
10
|
|
III
|
31
|
25.00
|
5.79
|
93
|
25
|
6
|
- Group 1: low-dose Sabin IPV group. Group 2: medium-dose Sabin IPV group. Group 3: high-dose Sabin IPV group. Group 4: control Sabin IPV group. Group 5: control Salk IPV group
